Globavir is focused on commercializing re-purposed drugs for controlling diseases with large unmet medical needs such as Coronavirus, Dengue Fever, Ebola, and Chikungunya. Globavir’s lead investigational drug GBV-006, is a novel drug combination that targets a host cells machinery essential for Vesicle Trafficking, which is essential for a virus’s ability to enter a cell, assemble and exit. Because the pathway to discovery of new small-molecule drugs take a long time to reach the clinic, Globavir has taken advantage of the cost-saving and time-saving benefits of drug-re-purposing. GBV-006 is a combination of two FDA approved drugs and has shown efficacy in both in vitro models as well as in vivo models affecting both viral load and mortality.